New Staging and Response Criteria for Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Radiologic Clinics of North America

Volumn 46, Issue 2, 2008, Pages 213-223

  Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Hodgkin lymphoma; Non Hodgkin lymphoma; Positron emission tomography scan; Response criteria

Indexed keywords

FLUORODEOXYGLUCOSE;

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REMISSION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 46449085782     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2008.03.003     Document Type: Review

References (67)

1. Grillo-López A.J., Cheson B.D., Horning S.J., et al. Response criteria for NHL: importance of normal lymph node size and correlations with response rates. Ann Oncol 11 (2000) 399-408
2. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an International Workshop to standardize response criteria for non-Hodgkin lymphomas. J Clin Oncol 17 (1999) 1244-1253
3. Surbone A., Longo D.L., DeVita Jr. V.T., et al. Residual abdominal masses in aggressive non-Hodgkin lymphoma after combination chemotherapy: significance and management. J Clin Oncol 6 (1988) 1832-1837
4. Radford J.A., Cowan R.A., Flanagan M., et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin disease. J Clin Oncol 6 (1988) 940-946
5. Bangerter M., Moog F., Buchmann I., et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin disease. Ann Oncol 9 (1998) 1117-1122
6. 18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol 19 (2001) 414-419
7. Spaepen K., Stroobants S., Dupont P., et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102 (2003) 53-59
8. Spaepen K., Stroobants S., Dupont P., et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin lymphoma. Ann Oncol 13 (2002) 1356-1363
9. Jerusalem G., Beguin Y., Fassotte M.F., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin disease. Haematologica 86 (2001) 266-273
10. Jerusalem G., Beguin Y., Fassotte M.F., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin disease and non-Hodgkin lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94 (1999) 429-433
11. Jerusalem G., Beguin Y., Najjar F., et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin lymphoma (NHL). Ann Oncol 12 (2001) 825-830
12. Jerusalem G., Warland V., Najjar F., et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin disease and non-Hodgkin lymphoma. Nucl Med Commun 20 (1999) 13-20
13. Zinzani P.L., Magagnoli M., Chierichetti F., et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 10 (1999) 1141-1143
14. 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98 (2001) 2930-2934
15. Naumann R., Vaic A., Beuthien-Baumann B., et al. Prognostic value of popsitron emission tomography in the evalaution of post-treatment residual mass in patients with Hodgkin disease and non-Hodgkin lymphoma. Br J Haematol 115 (2001) 793-800
16. Kostakoglu L., Leonard J.P., Kuji I., et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 94 (2002) 879-888
17. Naumann R., Beuthien-Baumann B., Reiss A., et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin lymphoma. Br J Cancer 90 (2004) 620-625
18. Munker R., Glass J., Griffeth L.K., et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin disease. Ann Oncol 15 (2004) 1699-1704
19. Mikhaeel N.G., Hutchings M., Fields P.A., et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16 (2005) 1514-1523
20. Juweid M., Wiseman G.A., Vose J.M., et al. Response assessment of aggressive non-Hodgkin lymphoma by integrated International Workshop criteria (IWC) and 18F-fluorodeoxyglucose positron emission tomography (PET). J Clin Oncol 23 (2005) 4652-4661
21. 18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106 (2005) 1376-1381
22. Hutchings M., Loft A., Hansen M., et al. Positron emission tomography with or without computed tomography in the primary staging of Hodgkin lymphoma. Haematologica 91 (2006) 482-489
23. Querellou S., Valette F., Bodet-Milin C., et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin lymphoma and Hodgkin disease. Ann Hematol 85 (2006) 759-767
24. Gallamini A., Rigacci L., Merli F., et al. Predictive value of positron emission tomography performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin disease. Haematologica 91 (2006) 475-481
25. Hutchings M., Loft A., Hansen M., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 (2006) 52-59
26. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Use of positron emission tomography for response assessment of lymphoma: consensus recommendations of the Imaging Subcommittee of the International Harmonization Project in Lymphoma. J Clin Oncol 25 (2007) 571-578
27. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579-586
28. Seam P., Juweid M.E., and Cheson B.D. The role of FDG-PET scans in patients with lymphoma. Blood 110 (2007) 3507-3516
29. Carbone P.P., Kaplan H.S., Musshoff K., et al. Report of the committee on Hodgkin disease staging classification. Cancer Res 31 (1971) 1860-1861
30. Newman J.S., Francis J.R., Kaminski M.S., et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 190 (1994) 111-116
31. Thill R., Neuerburg J., Fabry U., et al. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin 36 (1997) 234-239 [in German]
32. Moog F., Bangerter M., Diederichs C.G., et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]-D-glucpse)FDG) PET in nodal staging. Radiology 203 (1997) 795-800
33. Moog F., Bangerter M., Diederichs C.G., et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206 (1998) 475-481
34. Buchmann I., Reinhardt M., Elsner K., et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 91 (2001) 889-899
35. Blum R.H., Seymour J.F., Wirth A., et al. Frequent impact of [18F] Fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin lymphoma. Clin Lymphoma 4 (2004) 43-49
36. Partridge S., Timothy A., O'Doherty M.J., et al. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin disease: influence on patient management in a single institution. Ann Oncol 11 (2000) 1273-1279
37. Weihrauch M.R., Re D., Bischoff S., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial stsaging of patients with Hodgkin disease. Ann Hematol 81 (2002) 20-25
38. Menzel C., Dobert N., Mitrou P., et al. Positron emission tomography for the staging of Hodgkin lymphoma - increasing the body of evidence in favor of the method. Ann Oncol 41 (2002) 430-436
39. Schaefer N.G., Hany T.F., Taverna C., et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging - do we need contrast-enhanced CT?. Radiology 232 (2004) 823-829
40. 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the stasging and restaging of patients with lymphoma. Cancer 104 (2005) 1066-1074
41. Moog F., Bangerter M., Kotzerke J., et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. Blood 16 (1998) 603-609
42. Carr R., Barrington S.F., Madan B., et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91 (1998) 3340-3346
43. Pakos E.E., Fotopoulos A.D., and Ioannidis J.P. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46 (2005) 958-963
44. Rodriguez-Vigil B., Gomez-Leon N., Pinilla I., et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 47 (2006) 1643-1648
45. Freudenberg LS, Antoch G, Schütt P, et al. FDG-PET/CT in restaging of patients with lymphoma. Eur J Nucl Med Mol Imaging, in press.
46. Tatsumi M., Cohade C., Nakamoto Y., et al. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 237 (2005) 1038-1045
47. Kwee T.C., Kwee R.M., and Nievelstein R.A. Imaging in stagin of malignant lymphoma: a systematic review. Blood 111 (2008) 504-516
48. La Fougere C., Hundt W., Brockel N., et al. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin disease and non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 33 (2006) 1417-1425
49. Pfistner B., Diehl V., and Cheson B. International harmonization of trial parameters in malignant lymphoma. Eur J Haematol Suppl 75 66 (2005) 53-54
50. 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun 26 (2005) 689-694
51. Olsen K., Sohi J., Abraham T., et al. Initial validation of standardized quantitative (visual) criteria for FDG PET assessment of residual masses following lymphoma therapy. Proc Radiol Soc North Amer (2006) 323 [abstract 355:E323-302]
52. Zinzani P.L., Tani M., Fanti S., et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin disease patients. Ann Oncol 17 (2006) 1296-1300
53. Kostakoglu L., Goldsmith S.J., Leonard J.P., et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 107 (2006) 2678-2687
54. Gallamini A., Hutchings M., Rigacci L., et al. Early interim 2-[18F]fluoro-2-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced stage Hodgkin lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25 (2007) 3746-3752
55. Hoppe R.T., Advani R.H., Bierman P.J., et al. Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4 3 (2006) 210-230
56. Zelenetz A.D., Advani R.H., Buadi F., et al. Non-Hodgkin lymphoma: clinical practice guidelines in oncology. J Natl Compr Canc Netw 4 3 (2006) 258-310
57. Weeks J.C., Yeap B.Y., Canellos G.P., et al. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 9 (1991) 1196-1203
58. Oh Y.K., Ha C.S., Samuels B.I., et al. Stages I-III follicular lymphoma: role of CT of the abdomen and pelvis in follow-up studies. Radiology 210 (1999) 483-486
59. Foltz L.M., Song K.W., and Connors J.M. Who actually detects relapse in Hodgkin lymphoma: patient or physician. Blood 104 part 1 (2004) 853-854 [abstract 3124]
60. Liedtke M., Hamlin P.A., Moskowitz C.H., et al. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly treated patient population. Ann Oncol 17 (2006) 909-913
61. Jerusalem G., Beguin Y., Fassotte M.F., et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin disease. Ann Oncol 14 (2003) 123-130
62. Zinzani P.L., Stefoni V., Ambrosini V., et al. FDG-PET in the serial assessment of patients with lymphoma in complete remission. Blood 110 part 1 (2007) 71 [abstract 216]
63. Hoffmann M., Kletter K., Diemling M., et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 10 (1999) 1185-1189
64. Elstrom R., Guan L., Baker G., et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101 (2003) 3875-3876
65. Karam M., Novak L., Cyriac J., et al. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 107 (2006) 175-183
66. Hoffmann M., Wöhrer S., Becherer A., et al. 18F-fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol 17 (2006) 1761-1765
67. Lewis P.J., and Salama A. Uptake of fluorine-18-flouorodeoxyglucose in sarcoidosis. J Nucl Med 35 (1994) 1647-1649